GlassScriptPhysician profile
Ervin Szoke
NPI 1467485946
$13,913.07
in general payments reported to CMS, 2019-2025
49 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $895 · 2021: $1,516 · 2022: $1,504 · 2023: $7,905 · 2024: $818 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,489 · Food and Beverage: $2,930 · Travel and Lodging: $304 · Long Term Medical Supply Or Device Loan: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,488.86 |
| Food and Beverage | $2,930.44 |
| Travel and Lodging | $303.97 |
| Long Term Medical Supply Or Device Loan | $109.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $6,182.27 | 2023 | |
| Sanofi-Aventis U.S. LLC | $830.58 | 2019-2023 | |
| Mannkind Corporation | $571.80 | 2019-2023 | Afrezza |
| Novo Nordisk INC | $556.50 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $475.15 | 2021-2024 | Omnipod |
| Amgen INC. | $432.54 | 2019-2024 | Repatha |
| Abbott Laboratories | $349.50 | 2020-2025 | Freestyle Copilot, Freestyle Libre 3 |
| Lilly USA, LLC | $326.15 | 2020-2024 | Jardiance, Mounjaro, Lyumjev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.27 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Medtronic, INC. | $302.21 | 2021-2024 | Minimed 780g, Minimed 770g |
| Dexcom, INC. | $291.13 | 2021-2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $288.63 | 2020-2024 | Unithroid |
| Amarin Pharma, INC. | $268.55 | 2019-2022 | |
| Abbvie INC. | $225.85 | 2019-2024 | Synthroid |
| Radius Health, INC. | $217.03 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ervin Szoke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.